Molecularly-imprinted polymer-base bulk optode for the determination of ivabradine hydrochloride in Procoralan®

Abstract

IVH may be administered orally twice per day for treating heart failure, sinus rhythm, heart-related chest pain and angina pectoris, and its overdose may cause problems such as blurred vision, uncontrolled blood pressure, prolonged bradycardia, and others. A molecularly imprinted polymer-based bulk optode, miptode, was constructed for the determination of ivabradine hydrochloride (IVH) in its pharmaceutical preparation Procoralan®. The molecularly-imprinted polymers (MIPs) were prepared in different ratios, and MIP3 had the highest imprinting factor (1.6) as an ionophore in the miptode preparation. The miptode was prepared using weight ratios of 30% PVC polymer, 62% nitrophenyl octyl ether (NPOE) plasticizer, 6% MIP3 ionophore, 1% tetraphenyl borate derivative (TPB) ion-exchanger, and 1% ETH7075 chromoionophore; this miptode exhibited an absorbance increase at 530 nm in the concentration range of 10⁻²–10⁻⁵ M with a detection limit of 3.1 μM using Tris–HCl buffer of pH 7.2. The miptode was imaged using AFM, and showed the dissolution of all components except MIP particles which exhibited restricted solubility. However, the incorporation of MIP3 as an ionophore improved the selectivity coefficient over the interfering species that may exist in the pharmaceutical formulation to an extent that was not reported before; e.g. coefficients of IVH over sodium, magnesium, and glucose were improved by 5, 4 and 2 orders, when compared to the previous sensor that operated with the molecular interaction mechanism. The selectivity improvement in miptode is due to the Key-Lock fitting (host-guest molecular recognition) between the MIP particles and the template IVH molecule which is transduced with the ion-exchange process of the chromoionophore. The miptode has a response time of 1–2 minutes, and a reliable lifetime of two months. The miptode was applied successfully for the determination of IVH in the pharmaceutical preparation Procoralan® with recovery values of 89–99.8% with low standard deviations of <1.2.